These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

566 related items for PubMed ID: 16254428

  • 1. Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.
    Suh GH, Jung HY, Lee CU, Oh BH, Lee SK, Lee N, Kim J, Kee BS, Ko D, Kim YH, Ju YS, Hong I, Choi S, Korean Galantamine Study Group.
    Dement Geriatr Cogn Disord; 2006; 21(1):33-9. PubMed ID: 16254428
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease.
    Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD, Rosiglitazone in Alzheimer's Disease Study Group.
    Pharmacogenomics J; 2006; 6(4):246-54. PubMed ID: 16446752
    [Abstract] [Full Text] [Related]

  • 3. Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease.
    Choi SH, Kim SY, Na HR, Kim BK, Yang DW, Kwon JC, Park MY.
    Dement Geriatr Cogn Disord; 2008; 25(5):445-50. PubMed ID: 18401173
    [Abstract] [Full Text] [Related]

  • 4. Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis.
    Kleiman T, Zdanys K, Black B, Rightmer T, Grey M, Garman K, Macavoy M, Gelernter J, van Dyck C.
    Dement Geriatr Cogn Disord; 2006; 22(1):73-82. PubMed ID: 16699282
    [Abstract] [Full Text] [Related]

  • 5. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease.
    Brodaty H, Corey-Bloom J, Potocnik FC, Truyen L, Gold M, Damaraju CR.
    Dement Geriatr Cogn Disord; 2005; 20(2-3):120-32. PubMed ID: 15990426
    [Abstract] [Full Text] [Related]

  • 6. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).
    Erkinjuntti T, Gauthier S, Bullock R, Kurz A, Hammond G, Schwalen S, Zhu Y, Brashear R.
    J Psychopharmacol; 2008 Sep; 22(7):761-8. PubMed ID: 18308781
    [Abstract] [Full Text] [Related]

  • 7. A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population.
    Suh GH, Yeon Jung H, Uk Lee C, Hoon Oh B, Nam Bae J, Jung HY, Ju YS, Kil Yeon B, Park J, Hong I, Choi S, Ho Lee J, Korean Galantamine Study Group.
    Clin Ther; 2004 Oct; 26(10):1608-18. PubMed ID: 15598477
    [Abstract] [Full Text] [Related]

  • 8. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
    Bizzarro A, Marra C, Acciarri A, Valenza A, Tiziano FD, Brahe C, Masullo C.
    Dement Geriatr Cogn Disord; 2005 Oct; 20(4):254-61. PubMed ID: 16103669
    [Abstract] [Full Text] [Related]

  • 9. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease.
    Aerssens J, Raeymaekers P, Lilienfeld S, Geerts H, Konings F, Parys W.
    Dement Geriatr Cogn Disord; 2001 Oct; 12(2):69-77. PubMed ID: 11173877
    [Abstract] [Full Text] [Related]

  • 10. A naturalistic study of galantamine for Alzheimer's disease.
    Brodaty H, Woodward M, Boundy K, Barnes N, Allen G, NATURE Investigators.
    CNS Drugs; 2006 Oct; 20(11):935-43. PubMed ID: 17044730
    [Abstract] [Full Text] [Related]

  • 11. Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine.
    Bullock R, Erkinjuntti T, Lilienfeld S, GAL-INT-6 Study Group.
    Dement Geriatr Cogn Disord; 2004 Oct; 17(1-2):29-34. PubMed ID: 14560062
    [Abstract] [Full Text] [Related]

  • 12. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
    Chu LW, Yik PY, Mok W, Chung CP.
    Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
    [Abstract] [Full Text] [Related]

  • 13. Galantamine treatment of vascular dementia: a randomized trial.
    Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C, GAL-INT-26 Study Group.
    Neurology; 2007 Jul 31; 69(5):448-58. PubMed ID: 17664404
    [Abstract] [Full Text] [Related]

  • 14. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.
    Biol Psychiatry; 2004 Nov 01; 56(9):670-6. PubMed ID: 15522251
    [Abstract] [Full Text] [Related]

  • 15. Two galantamine titration regimens in patients switched from donepezil.
    Engedal K, Davis B, Richarz U, Han J, Schäuble B, Andreasen N.
    Acta Neurol Scand; 2012 Jul 01; 126(1):37-44. PubMed ID: 21992111
    [Abstract] [Full Text] [Related]

  • 16. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial.
    Scarpini E, Bruno G, Zappalà G, Adami M, Richarz U, Gaudig M, Jacobs A, Schäuble B.
    J Alzheimers Dis; 2011 Jul 01; 26(2):211-20. PubMed ID: 21606568
    [Abstract] [Full Text] [Related]

  • 17. Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen.
    Thavichachart N, Phanthumchinda K, Chankrachang S, Praditsuwan R, Nidhinandana S, Senanarong V, Poungvarin N.
    Int J Clin Pract; 2006 May 01; 60(5):533-40. PubMed ID: 16700849
    [Abstract] [Full Text] [Related]

  • 18. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.
    Raskind MA, Peskind ER, Wessel T, Yuan W.
    Neurology; 2000 Jun 27; 54(12):2261-8. PubMed ID: 10881250
    [Abstract] [Full Text] [Related]

  • 19. Apolipoprotein E epsilon4 allele differently affects the patterns of neuropsychological presentation in early- and late-onset Alzheimer's disease patients.
    Marra C, Bizzarro A, Daniele A, De Luca L, Ferraccioli M, Valenza A, Brahe C, Tiziano FD, Gainotti G, Masullo C.
    Dement Geriatr Cogn Disord; 2004 Jun 27; 18(2):125-31. PubMed ID: 15211066
    [Abstract] [Full Text] [Related]

  • 20. Effects of galantamine in patients with mild Alzheimer's disease.
    Orgogozo JM, Small GW, Hammond G, Van Baelen B, Schwalen S.
    Curr Med Res Opin; 2004 Nov 27; 20(11):1815-20. PubMed ID: 15537482
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.